Definition & Pathophysiology

GERD is a chronic, often relapsing disorder characterized by the reflux of gastric (and duodenal) contents—acid, bile, pepsin, and pancreatic enzymes—into the esophagus, pharynx, or larynx, resulting in:

• Bothersome symptoms (e.g., heartburn, regurgitation), and/or
• Complications (e.g., erosive esophagitis, Barrett’s esophagus, strictures, pulmonary aspiration).

Key pathophysiological mechanisms include:

1. Transient lower esophageal sphincter relaxations (TLESRs)—the primary mechanism in non-erosive reflux disease (NERD) and most GERD cases.
2. Hypotensive lower esophageal sphincter (LES) pressure (<6 mmHg), often exacerbated by hiatal hernia (>3 cm).
3. Impaired esophageal clearance (reduced peristalsis or saliva production).
4. Delayed gastric emptying, particularly in diabetic gastroparesis or post-vagotomy states.

Epidemiology & Risk Factors

• Prevalence: ~15–20% of adults in Western countries have weekly symptoms; 5–10% meet criteria for moderate-to-severe disease.
• Strong risk factors:
  • Obesity (BMI ≥30; OR 2.5–3.0 for GERD)
  • Hiatal hernia (>3 cm, especially paraesophageal)
  • Pregnancy (progesterone-induced LES relaxation)
  • Smoking (reduces LES pressure and salivary bicarbonate)
  • Medications: benzodiazepines, calcium channel blockers, nitrates, theophylline, bisphosphonates, NSAIDs
  • Genetic predisposition (heritability ~30–40%; FOXP2, MTSR1 loci implicated)

Clinical Presentation & Symptom Profile

Typical Esophageal Symptoms

• Heartburn: Retrosternal burning rising toward the neck; worse supine or postprandially.
• Regurgitation: Effortless backflow of gastric contents; more specific than heartburn for objective GERD (positive likelihood ratio [LR+] = 5.2–10.6).

Atypical/Extraesophageal Symptoms (Controversial association—require rigorous evaluation)

Critical clinical pearl: Extraesophageal symptoms alone are insufficient to diagnose GERD. Up to 40% of patients with chronic cough or laryngitis have no objective evidence of reflux on pH-impedance monitoring.

Diagnostic Evaluation: A Stepwise Approach

1. Clinical Diagnosis Based on Symptom Thresholds

-GERD is diagnosed clinically when a patient reports at least weekly troublesome heartburn and/or regurgitation (ACG definition of “symptomatic GERD”).

2. When to Perform Diagnostic Testing?

(Based on ACG Grade: Strong for indicated scenarios)

Diagnostic Modalities: Technical Nuances

• Upper Endoscopy:
  • Use the Los Angeles (LA) Classification for esophagitis grading (A–D). LA C/D predicts higher recurrence risk and Barrett’s progression.
  • Biopsy protocol: 5–8 biopsies from squamocolumnar junction + every 1–2 cm proximally—even if endoscopy is negative (to diagnose EoE, active inflammation).
• pH Monitoring:
  • Ambulatory pH monitoring with impedance (pH-impedance) is now standard of care (replaced older catheter-based tests). Detects both acid and non-acid reflux.
  • Critical: Patient must be off PPIs for ≥7 days (or up to 14 days for full acid rebound) prior to diagnostic monitoring. Use De Meester score (composite of 6 parameters); >5.2 indicates abnormal reflux burden.
  • Diagnostic yield: Positive in only ~60% of NERD patients; normal result does not exclude GERD if clinical suspicion is high.
• Esophageal Manometry:
  • Indicated before surgery or endoscopic therapy to rule out achalasia, jackhammer esophagus, or hypomotility disorders. Performed with high-resolution manometry (HRM).
  • Excludes motility disorders mimicking GERD—critical before magnetic sphincter augmentation.

Emerging Tools

• Wireless pH capsule (Bravo): Longer recording (96 h), better patient comfort—but contraindicated in strictures, coagulopathy, or implanted devices. Cannot assess non-acid reflux.
• Reflux symptom association probability (SAP) analysis: Statistical correlation between symptoms and reflux episodes (SAP ≥95% = significant association). Superior to symptom index alone.

Management: Evidence-Based Algorithms

1. Lifestyle Modifications

Clinical tip: Patients often over-restrict diets. Use a dietary provocation test: reintroduce high-fat meals, caffeine, chocolate one at a time while tracking symptoms.

2. Pharmacotherapy

Proton Pump Inhibitors (PPIs)

• First-line empiric therapy:
  • Standard dose (e.g., omeprazole 20 mg, pantoprazole 40 mg) once daily, 30–60 min before breakfast for 8 weeks.
  • Efficacy: heals erosive esophagitis in 85–90% at 8 weeks; NERD response ~50–60%.
• Maintenance therapy decisions:Patient CategoryRecommendationLA A/B esophagitis, no Barrett’sWean PPI: Try stepping down to H2RA, on-demand PPI, or discontinuation after 8 weeks (ACG conditional)LA C/D esophagitis or Barrett’s esophagusLifelong maintenance; lowest effective dose (e.g., alternate-day PPI if feasible). Annual surveillance endoscopy for Barrett’s per AGA 2023 guidelines.

PPI Optimization in Non-Responsive Cases

1. Confirm adherence: 25% of non-response is due to improper timing or underdosing.
2. Switch or escalate:
   • Partial response: Increase to twice daily (e.g., take first dose before breakfast, second before dinner).
   • No response after 4–8 weeks: Re-evaluate diagnosis—consider EoE (requires esophageal biopsies), functional heartburn (diagnosis of exclusion), or non-GERD chest pain.
3. Add bedtime H2RA (e.g., famotidine 40 mg):
   • Only effective if nocturnal acid breakthrough confirmed by pH monitoring.
   • Tachyphylaxis limits benefit beyond 4 weeks—avoid long-term use.

Alternative Agents

• Potassium-Competitive Acid Blockers (P-CABs):
  • Vonoprazan (FDA-approved 2023): Faster, more sustained acid suppression than PPIs; superior healing at 4 weeks for LA A–C esophagitis (KEYNOTE-89 trial). Caution: potential for Clostridioides difficile and * Campylobacter* risk (RR 1.5–2.0 with long-term use).
• Sodium alginate (Gaviscon Advance): Forms protective raft on gastric contents—effective for mild, intermittent GERD (NNT = 4; Cochrane 2022). Safe in pregnancy.
• TLESR inhibitors: Baclofen (10–20 mg TID) reduces reflux episodes by 70% but limited by dizziness/nausea. Reserved for refractory cases under specialist care.
• Pregnancy-safe options: Sucralfate (non-absorbed), H2RAs, or alginate-based therapy first-line; PPIs second-line if needed.

3. Endoscopic & Surgical Therapies

Indications

• Objective GERD (positive pH-impedance/endoscopy) + symptoms refractory to optimized medical therapy
• Patient preference (aversion to lifelong PPIs)

Critical decision point: Do not offer endoscopic/surgical therapy without objective confirmation of GERD. Up to 30% of “refractory GERD” cases are functional disorders with no acid reflux on monitoring.

Special Populations

Barrett’s Esophagus

• Surveillance intervals (AGA 2023):
  • <1 cm (short-segment),无异型增生 → every 3–5 yr
  • Low-grade dysplasia → repeat EGD in 3 mo + high-definition white light + chromoendoscopy
  • High-grade dysplasia → Endoscopic mucosal resection (EMR) ± ablation
• PPI dosing: High-dose (e.g., esomeprazole 40 mg BID) to maintain pH >4 for >23 h/day—may slow metaplasia progression.

GERD in Children & Elderly

• Children <12 y: Regurgitation is normal up to age 1; treat only if complications (failure to thrive, apnea, hematemesis) or esophagitis present.
• Elderly: Higher risk of PPI-related adverse effects (C. diff, fractures, CKD). Prioritize lowest effective dose and deprescribe when possible.

Key Knowledge Gaps & Future Directions

1. Microbiome-based diagnostics: Duodenal aspiration showing Streptococcus enrichment correlates with GERD severity (Gut 2024).
2. Refractory GERD subphenotyping: Differentiating acid-reflux, weakly acidic reflux, and non-reflux hypersensitivity guides therapy.
3. Novel agents: Netupitant/palonosetron (NK1 antagonist) reduces TLESRs in Phase II trials.

Summary of Strength-of-Recommendation Taxonomy (GRADE)

Conclusion: GERD management has evolved beyond symptom control to objectively confirm disease, risk-stratify for complications, and personalize therapy. Always rule out non-GERD etiologies in atypical presentations, utilize pH-impedance when diagnosis remains uncertain, and reserve advanced therapies for confirmed refractory cases. Adherence to guideline-based algorithms reduces unnecessary PPI use—a major public health concern—and improves long-term outcomes.

Sources: ACG Clinical Guideline 2023, AGA Institute Guidelines (2023), ASGE Standards of Practice (2024), NEJM Reviews (2022–2024), Cochrane Database Syst Rev (2022–2023).